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Abstract Since the generation of superoxide and hydrogen
peroxide by NADPH oxidase and nitric oxide (NO) by NO
synthase (NOS) in granulocytes is NADPH-dependent, we
investigated the production of NO, superoxide and H2O2 in
glucose 6-phosphate dehydrogenase (G6PD)-deficient human
granulocytes. Our results showed that upon stimulation with
either 5 Wg/ml of lipopolysaccharide (LPS) or 10 WM of phorbol
12-myristate 13-acetate (PMA), the production of nitrite in
normal granulocytes was elevated, 252 þ 135% and 239 þ 72%,
respectively, compared to the resting stage. In contrast, G6PD-
deficient granulocytes did not produce more nitrite upon
stimulation with either LPS or PMA compared to the resting
stage. Western blot analysis indicated a normal expression
pattern of inducible NOS in G6PD-deficient granulocytes. In
addition, the production of H2O2 and superoxide was also
significantly impaired in G6PD-deficient granulocytes compared
to control cells. These data demonstrate that G6PD deficiency
causes an impairment in the production of NO, superoxide and
H2O2.
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1. Introduction
Glucose 6-phosphate dehydrogenase (G6PD) de¢ciency is
one of the most common enzymopathies a¡ecting over 200
million people world-wide [1,2]. The de¢ciency predisposes
subjects to neonatal jaundice, drug or infection mediated he-
molytic crisis, favism and, less commonly, to chronic non-
spherocytic hemolytic anemia [3,4]. Since its discovery, many
advances have been made in the ¢eld of G6PD research, but
the advances have been unbalanced. The molecular biology of
G6PD de¢ciency has largely been elucidated [5^10]. In con-
trast, the pathophysiology of G6PD de¢ciency, particularly
the chronic e¡ects of G6PD de¢ciency, is far from completely
understood.
Since the major biochemical function of G6PD in human
cells is to generate NADPH, the clinical relevance of G6PD
de¢ciency may well be related to the changes in redox status
in G6PD-de¢cient cells. Such a disturbance in redox status
can a¡ect certain cellular processes leading to clinical mani-
festations. For example, neutrophil dysfunction and increased
susceptibility to infection have been reported in severe G6PD
de¢ciency [11,12]. The detailed mechanism of such dysfunc-
tion has not been fully elucidated. Nitric oxide (NO) gener-
ated from L-arginine by the inducible NO synthase (iNOS) is
regarded as a defense e¡ector molecule with cytotoxic/cyto-
static and microbicidal/microstatic activity. The major outer
membrane component of Gram-negative bacteria, lipopoly-
saccharide (LPS), is a potent activator of macrophage re-
sponses involved in the host defense against infection [13].
Since the generation of NO by NOS and other reactive oxy-
gen species (ROS) by NADPH oxidase in human cells is
NADPH-dependent [11^13], we investigated the production
of NO and ROS by G6PD-de¢cient granulocytes and normal
controls after the addition of LPS or phorbol myristate ace-
tate (PMA) as a stimulant.
2. Materials and methods
2.1. Samples and other materials
After obtaining informed consent, blood specimens were collected
in tubes containing anticoagulant from normal and G6PD-de¢cient
individuals. G6PD-de¢cient individuals selected in this study all had
the Taiwan-Hakka variant (G6PD1376T) [8,9]. This means that they
have the same molecular defect with a mutation of G to T in the
cDNA at bp 1376 of their G6PD gene. A blood specimen from a
patient with chronic granulomatous disease (CGD), a hereditary de-
fect in NADPH oxidase, was also obtained for comparison. Unless
stated otherwise, all biochemicals were purchased from Sigma (St.
Louis, MO, USA). L-[2,3,4,5-3H]Arginine hydrochloride was obtained
from Amersham International (Amersham, Bucks., UK).
2.2. Isolation of granulocytes
To separate granulocytes, 3.5 ml of Histopaque-1119 (Sigma) was
added to 5 ml of whole blood in a 15 ml centrifuge tube and the
mixture was centrifuged at 700Ug for 25 min. The middle layer con-
taining mostly granulocytes was collected. The granulocytes were
washed twice with phosphate bu¡ered saline (PBS), pH 7.4, prior to
subsequent experiments.
2.3. G6PD activity
The G6PD activity in fresh blood cells was quantitatively measured
using a No. 345-B kit supplied by Sigma as previously described [9].
2.4. Measurement of nitrite production as an assay of NO synthesis
Nitrite production was measured in the supernatant of granulocytes
by the Griess reaction [14]. Brie£y, 107 granulocytes cultured in phen-
ol red-free DMEM were stimulated with various concentrations of
LPS or PMA for 24 h. The medium was centrifuged and aliquots
of the supernatant were mixed with an equal volume of Griess reagent
(1% sulfanilamide/0.1% naphthylenediamine dihydrochloride/2.5%
H3PO4) and then incubated at room temperature for 10 min. The
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nitrite concentration in the medium was determined with sodium ni-
trite as standard. Absorbance spectroscopy of the samples was per-
formed at 550 nm using a Multiskan II plate reader (Titertek).
2.5. Western blot analysis of iNOS
Granulocytes grown in 35 mm dishes were incubated with LPS for
24 h in DMEM containing serum. Cells were washed twice with ice-
cold PBS, and lysed in 1 ml of ice-cold lysis bu¡er (50 mM Tris-HCl,
pH 7.4, 1% Nonidet P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl
£uoride, 5 Wg/ml aprotinin). The cells were then sonicated for 5 min
and centrifuged at 14 000Ug at 4‡C for 10 min. The supernatant was
collected and protein content determined using a Bio-Rad kit. Cell
lysate was mixed with Laemmli bu¡er and boiled for 5 min. Electro-
phoresis was carried out by adding equal amounts of protein (60 Wg/
lane) to a 7.5% SDS-polyacrylamide gel. Proteins were transferred
onto nitrocellulose membrane and incubated with blocking solution
(5% fat-free milk in PBS with 0.1% Tween 20, PBST) at 4‡C for 2 h.
The membranes were then incubated with puri¢ed polyclonal rabbit
IgG antibody against murine iNOS at 1:500 dilution in the above
solution overnight at 4‡C. Blots were washed three times in PBST.
Blots were further incubated for 1 h with the goat anti-rabbit IgG
antibody conjugated to horseradish peroxidase at 1:2500 dilution in
PBST. The enhanced chemiluminescence kit was used for detection
and exposed to hyper¢lm MP.
2.6. Measurement of hydrogen peroxide and superoxide produced by
granulocytes using a £uorescent method
This method utilized the conversion of non-£uorescent 4-hydroxy-
phenylacetic acid (4-HPAA) into £uorescent 6,6P-dihydroxy-(1,1P-bi-
phenyl)-3,3P-diacetic acid in the presence of horseradish peroxidase
and H2O2. Since superoxide radicals could be quickly converted
into H2O2 by excess superoxide dismutase (SOD), one could measure
only H2O2 or both H2O2 and superoxide by not adding SOD or
adding excess SOD, respectively. To measure the generation of
H2O2 and superoxide, a modi¢ed protocol of Hyslop and Sklar [15]
was employed: to 1 ml of granulocyte suspension containing approx-
imately 3U105 granulocytes, 100 Wl of PMA (0.1 Wg/ml), 40 Wl of
NaN3 (5 mM), and 40 Wl of horseradish peroxidase (400 IU/ml)
were added with or without 40 Wl of SOD (1000 IU/ml). This reaction
mixture was preincubated in a 37‡C water bath with constant shaking
for 5 min and 40 Wl of 4-HPAA (50 mM) was then added, vortexed
and incubated with constant shaking in a 37‡C water bath. At appro-
priate time intervals, 250 Wl of the reaction mixture were taken into a
micro-centrifuge tube and centrifuged at 12 000 rpm for 5 min. After
centrifugation, 200 Wl of the supernatant was pipetted into a test
tube containing 0.5 ml of 60 mM potassium phosphate bu¡er, pH
7.4 and incubated in the dark at 37‡C with constant shaking. After
incubating for 30 min, 1.5 ml of chilled 2 mM KCN in 0.1 M Na2CO3
was added to the supernatant. Fluorescence representing the amount
of H2O2 and superoxide was then measured with excitation at 318 nm
and emission at 405 nm using a Perkin-Elmer MPF-3 spectro£uorom-
eter.
3. Results
3.1. G6PD activity in normal and G6PD-de¢cient blood cells
All G6PD-de¢cient individuals carried the Taiwan-Hakka
variant (G6PD1376T) as con¢rmed by molecular analysis as
previously described [8,9]. This means that they all had the
same molecular defect with a mutation of G to T in cDNA
1376 of their G6PD gene. As shown in Table 1, G6PD activity
in red blood cells (RBCs) of these G6PD-de¢cient individuals
was not totally absent but much lower (28.0 þ 1.4 U/1012 cells)
than that in normal RBCs (213.5 þ 6.4 U/1012 cells) and these
data were similar to those reported previously [11]. G6PD
activity of granulocytes from G6PD-de¢cient individuals
(14 491 þ 2345 U/1012 cells) was also signi¢cantly (P6 0.001)
lower than that found in normal granulocytes (42 529 þ 2162
U/1012 cells) but the degree of de¢ciency was not as severe as
in RBCs.
3.2. NO production
Having recon¢rmed the much lower G6PD activity in gran-
ulocytes of the G6PD-de¢cient individuals, we checked NO
production in the granulocytes of these G6PD-de¢cient indi-
viduals. The production of NO in normal granulocytes was
increased greatly upon stimulation with either LPS or PMA as
seen in Table 2 where with 5 Wg/ml of LPS or 10 WM of PMA,
the production of NO in normal granulocytes was shown to
increase by 252 þ 135% and 239 þ 72% of the resting stage,
respectively. In contrast, the production of NO in G6PD-de-
¢cient granulocytes upon stimulation with LPS (5 Wg/ml) or
PMA (10 WM) was only 70 þ 26% and 76 þ 25% of the resting
stage, respectively (Table 2).
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Table 1
G6PD activity in normal and G6PD-de¢cient blood cells
Sample G6PD activity in WBCs G6PD activity in RBCs
(U/1012 cells) (U/1012 cells)
Normal (n = 4) 42 529 þ 2162 213.5 þ 6.4
G6PD-de¢cient (n = 3) 14 491 þ 2345 28.0 þ 1.4
The results are shown as mean þ S.D.
Table 2
Nitrite production and NOS activity in LPS- or PMA-stimulated normal and G6PD-de¢cient human granulocytes
Sample Nitrite production (% of resting) NOS activity (% of resting)
LPS (5 Wg/ml) PMA (10 WM) LPS (5 Wg/ml) PMA (10 WM)
Normal (n = 4) 252 þ 135 239 þ 72 328 þ 23 545 þ 79
G6PD-de¢cient (n = 3) 70 þ 26 76 þ 25 130 þ 37 86 þ 29
The results are shown as mean þ S.D.
Fig. 1. LPS-induced iNOS protein expression in granulocytes. Nor-
mal (left panel) and G6PD-de¢cient cells were incubated with LPS
(5 Wg/ml) for 24 h. Cells were harvested at 24 h for Western blot
analysis. This is a representative assay from two separate experi-
ments.
K.-J. Tsai et al./FEBS Letters 436 (1998) 411^414412
3.3. Western blot analysis of NOS
To determine whether the impaired NO production is due
to inadequate expression of NOS upon stimulation by LPS or
PMA, we performed Western blot analysis of NOS. Our data
clearly indicate that G6PD-de¢cient granulocytes had normal
expression of NOS upon stimulation (Fig. 1). In response to
LPS (5 Wg/ml) or PMA (10 WM), an inducible Ca2-independ-
ent 130 kDa NOS was produced in the normal granulocytes.
Likewise, G6PD-de¢cient granulocytes also produced a simi-
lar amount of this Ca2-independent 130 kDa NOS upon
stimulation with LPS (5 Wg/ml) or PMA (10 WM).
3.4. Generation of hydrogen peroxide and superoxide induced
by PMA
As shown above, the generation of NO, an NADPH-de-
pendent reaction, was severely a¡ected in G6PD-de¢cient
granulocytes. We checked whether the production of H2O2
and superoxide, which is also dependent on NADPH, was
a¡ected by G6PD de¢ciency. After 15 min of stimulation,
normal granulocytes produced 2.256 þ 0.955 nmol of H2O2
and 2.440 þ 0.362 nmol of superoxide per 105 cells, whereas
G6PD-de¢cient granulocytes produced signi¢cantly less
(P6 0.05): only 0.805 þ 0.924 nmol of H2O2 and
0.902 þ 0.525 nmol of superoxide per 105 cells (Table 3). For
comparison, we also examined the production of H2O2 and
superoxide in granulocytes from a patient with CGD. The
granulocytes in this patient had no functional NADPH oxi-
dase and hence produced no detectable H2O2 and superoxide
(Table 3). With longer PMA induction times (30 min and 60
min), both normal and G6PD-de¢cient granulocytes produced
more H2O2 and superoxide, but the increases in G6PD-de¢-
cient granulocytes were again substantially lower than in nor-
mal granulocytes (Figs. 2 and 3). Granulocytes from the pa-
tient with CGD produced virtually no detectable H2O2 and
superoxide at any PMA induction time point (Figs. 2 and 3).
4. Discussion
We demonstrate here that G6PD-de¢cient granulocytes, as
in RBCs, have lower G6PD activity. This decreased G6PD
activity in granulocytes apparently leads to the impaired pro-
duction of nitric oxide as well as H2O2 and superoxide upon
stimulation by LPS or PMA. As far as we know, this is the
¢rst report on impaired NO production in G6PD-de¢cient
cells.
As is known, lower G6PD activity in RBCs is a hallmark of
G6PD de¢ciency. However, very little information is available
concerning the activity of this enzyme in white blood cells
(WBCs) with di¡erent G6PD variants. In view of the low
G6PD activity in RBCs, it is natural to expect a low G6PD
activity in WBCs. It is interesting to note, therefore, that
granulocytes from individuals with G6PD1376T maintain one
third of the normal granulocyte G6PD activity level, while the
RBCs from these same individuals have only 12% of normal
RBC G6PD activity (Table 1). These ¢ndings concerning
G6PD activity in G6PD-de¢cient granulocytes and RBCs
are similar to those reported for an African G6PD variant,
Gd(minus) Matam [16]. This di¡erence in G6PD activity be-
tween granulocytes and RBCs may explain, in part, why acute
clinical problems are largely related to RBCs in G6PD de¢-
ciency.
Through its participation in the pentose phosphate shunt,
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Table 3
Generation of H2O2 and superoxide in PMA-stimulateda normal and G6PD-de¢cient human granulocytes
Sample H2O2 generation Superoxide generation
(nmol/105 granulocytes) (nmol/105 granulocytes)
3PMA +PMA 3PMA +PMA
Control (n = 12) UDb 2.26 þ 0.96 0.13 þ 0.11 2.44 þ 0.36
G6PD-de¢cient (n = 4) UD 0.81 þ 0.92 0.16 þ 0.23 0.90 þ 0.53
CGD (n = 1) UD UD UD UD
The results are shown as mean þ S.D.
aPMA stimulation was carried out for 15 min.
bUD: undetectable.
Fig. 2. PMA-induced H2O2 production in granulocytes. H2O2 pro-
duction by normal, G6PD-de¢cient or CGD granulocytes was meas-
ured using a £uorescence method. Standard deviations are shown as
bars in each set of experiments. No standard deviation is shown for
the CGD granulocytes because only one case is reported in our
study.
Fig. 3. PMA-induced superoxide production in granulocytes. Super-
oxide production by normal, G6PD-de¢cient or CGD granulocytes
was measured using a £uorescence method. Mean and standard de-
viation are shown for each set of experiment. No standard deviation
is shown for the CGD granulocytes because only one case is re-
ported in our study.
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G6PD provides a constant source of NADPH as reducing
equivalents that are essential to a variety of metabolic func-
tions. This is highlighted by the fact that NADPH is a cofac-
tor for NOS activity. It has been observed that G6PD and
NOS co-localize in brush cells of the gastric and pancreatic
duct epithelial cells [17]. An increase in NO synthesis was
found to parallel an increase in G6PD activity in activated
bone marrow macrophages [18]. This ¢nding could be of rele-
vance to our observation that G6PD-de¢cient cells undergo
no change in NO production upon stimulation by LPS or
PMA.
Our ¢nding that G6PD-de¢cient granulocytes produce far
less NO than normal granulocytes upon stimulation with ei-
ther LPS or PMA (Table 2) may have pathophysiologic im-
plications in G6PD de¢ciency. NO can react with superoxide
to form peroxynitrite [19], which is an important bactericidal
agent during phagocytosis [20]. In fact, a study using activated
human neutrophils indicates that the kinetics of NO and
superoxide release favor the formation of peroxynitrite [20].
An impaired production of NO may render the production of
peroxynitrite in neutrophils abnormal leading to defective mi-
crobicidal action. This ¢nding may help to explain the earlier
observations that severe G6PD de¢ciency can exhibit neutro-
phil dysfunction and increased susceptibility to infection
[11,12]. In addition, NO is known to play very important roles
in the cardiovascular system, including regulation of basal
blood pressure, inhibition of smooth muscle contraction, in-
hibition of platelet aggregation and many others [13]. Hence,
impairment in the production of NO under a stress condition
in G6PD-de¢cient cells may render G6PD-de¢cient individu-
als more susceptible to certain cardiovascular diseases. A pre-
liminary study from our laboratory indicates that among
adult males with high blood pressure, there is a higher inci-
dence (6.1%) of G6PD de¢ciency than in the general male
population (3.0%) in Taiwan (unpublished observation), sug-
gesting that G6PD de¢ciency may predispose a¡ected individ-
uals to high blood pressure. Whether G6PD de¢ciency also
causes an impaired production of NO in endothelial cells
leading to high blood pressure remains to be established.
In addition to decreased NO production, G6PD-de¢cient
granulocytes also exhibit an impairment in the generation of
H2O2 and superoxide upon stimulation with PMA (Table 3).
The decreased superoxide production upon stimulation is sim-
ilar to that reported by Pascale et al. [21] who found that
polymorphonuclear leukocytes (PMNs) from individuals car-
rying the Mediterranean variant of G6PD exhibit a 58% de-
crease in superoxide formation upon stimulation by 12-O-tet-
radecanoyl phorbol 13-acetate as compared to normal PMNs.
H2O2 was not monitored in their study. It should be pointed
out that both the Mediterranean variant and the Taiwan-Hak-
ka variant are class II variants as de¢ned by the World Health
Organization [22]. Since these G6PD-de¢cient granulocytes
still maintain more than 30% of the normal amount of
G6PD activity (Table 1), the reduction in H2O2 and super-
oxide production is not as severe as that in CGD granulo-
cytes, where no detectable H2O2 and superoxide production
was observed (Figs. 2 and 3). Nevertheless, the decrease in
generation of H2O2 and superoxide by G6PD-de¢cient
WBCs may help to further clarify the earlier observations
that severe G6PD de¢ciency is associated with neutrophil dys-
function and increased susceptibility to infection [11,12], be-
cause these ROS are important microbicidal agents in phag-
ocytes.
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